7th Circ. Declines To Revive Humira 'Patent Thicket' Claims
A Seventh Circuit panel on Monday refused to revive landmark private antitrust claims from Humira buyers accusing pharmaceutical giant AbbVie of using a "patent thicket" to illegally shield the blockbuster immunosuppressant...To view the full article, register now.
Already a subscriber? Click here to view full article